Association between the haemoglobin glycation index and 30-day and 365-day mortality in patients with heart failure admitted to the intensive care unit.

IF 3.4 3区 医学 Q2 ENDOCRINOLOGY & METABOLISM
Ziyu Guo, Yike Li, Shuoyan An, Jingang Zheng
{"title":"Association between the haemoglobin glycation index and 30-day and 365-day mortality in patients with heart failure admitted to the intensive care unit.","authors":"Ziyu Guo, Yike Li, Shuoyan An, Jingang Zheng","doi":"10.1186/s13098-025-01661-4","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The hemoglobin glycation index (HGI) represents the difference between the observed and predicted values of haemoglobin A1c (HbA1c). However, the association between HGI and prognosis of heart failure (HF) is not completely clarified yet and requires more investigation. This study aimed to explore the connection between HGI and mortality in HF patients.</p><p><strong>Methods: </strong>The data for the study were derived from the MIMIC-IV database from 2008 to 2019, a publicly available clinical database in intensive care. A linear regression equation between HbA1c and fasting blood glucose (FBG) was established to calculate predicted HbA1c. The endpoints were 30-day and 365-day all-cause mortality. Kaplan-Meier analysis was utilized to compare survival rates across groups differentiated by their HGI levels. The Cox regression models and restricted cubic spline (RCS) analysis were utilized to analyze the association between HGI and mortality.</p><p><strong>Results: </strong>The study collected a total of 2846 patients with HF (40.1% male), of whom 305 patients (10.7%) died within 30 days and 954 patients (33.5%) died within 365 days. Kaplan-Meier curves revealed patients with higher HGI had significantly higher mortality risks (log-rank P < 0.001). A high HGI was significantly associated with 30-day mortality (adjusted HR [aHR]: 2.36, 95% CI: 1.74-3.20, P < 0.001) and 365-day mortality (aHR: 1.40, 95% CI: 1.16-1.68, P < 0.001) after adjustment for potential confounders. Likewise, each unit increase in the HGI correlated with a 1.42-fold higher risk of 30-day mortality (aHR: 1.42, 95% CI: 1.28-1.57, P < 0.001) and 1.19-fold higher risk of 365-day mortality (aHR: 1.19, 95% CI: 1.11-1.68, P < 0.001). RCS analysis suggested an L-shaped nonlinear association between HGI and clinical endpoints (P for nonlinearity < 0.001), with an inflection point value of - 1.295. Subgroup analysis and sensitivity analysis revealed that the correlation between HGI and 30-day and 365-day all-cause mortality remained consistent.</p><p><strong>Conclusions: </strong>In ICU-admitted HF patients, HGI was independently associated with increased risks of 30-day and 365-day mortality and the identification of high HGI (> 0.709) provided a valuable tool for clinicians to detect high-risk populations. Integrating HGI into routine clinical practice might strengthen the prognosis-based decision making improve HF patient outcomes.</p>","PeriodicalId":11106,"journal":{"name":"Diabetology & Metabolic Syndrome","volume":"17 1","pages":"87"},"PeriodicalIF":3.4000,"publicationDate":"2025-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11916851/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetology & Metabolic Syndrome","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s13098-025-01661-4","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

Abstract

Background: The hemoglobin glycation index (HGI) represents the difference between the observed and predicted values of haemoglobin A1c (HbA1c). However, the association between HGI and prognosis of heart failure (HF) is not completely clarified yet and requires more investigation. This study aimed to explore the connection between HGI and mortality in HF patients.

Methods: The data for the study were derived from the MIMIC-IV database from 2008 to 2019, a publicly available clinical database in intensive care. A linear regression equation between HbA1c and fasting blood glucose (FBG) was established to calculate predicted HbA1c. The endpoints were 30-day and 365-day all-cause mortality. Kaplan-Meier analysis was utilized to compare survival rates across groups differentiated by their HGI levels. The Cox regression models and restricted cubic spline (RCS) analysis were utilized to analyze the association between HGI and mortality.

Results: The study collected a total of 2846 patients with HF (40.1% male), of whom 305 patients (10.7%) died within 30 days and 954 patients (33.5%) died within 365 days. Kaplan-Meier curves revealed patients with higher HGI had significantly higher mortality risks (log-rank P < 0.001). A high HGI was significantly associated with 30-day mortality (adjusted HR [aHR]: 2.36, 95% CI: 1.74-3.20, P < 0.001) and 365-day mortality (aHR: 1.40, 95% CI: 1.16-1.68, P < 0.001) after adjustment for potential confounders. Likewise, each unit increase in the HGI correlated with a 1.42-fold higher risk of 30-day mortality (aHR: 1.42, 95% CI: 1.28-1.57, P < 0.001) and 1.19-fold higher risk of 365-day mortality (aHR: 1.19, 95% CI: 1.11-1.68, P < 0.001). RCS analysis suggested an L-shaped nonlinear association between HGI and clinical endpoints (P for nonlinearity < 0.001), with an inflection point value of - 1.295. Subgroup analysis and sensitivity analysis revealed that the correlation between HGI and 30-day and 365-day all-cause mortality remained consistent.

Conclusions: In ICU-admitted HF patients, HGI was independently associated with increased risks of 30-day and 365-day mortality and the identification of high HGI (> 0.709) provided a valuable tool for clinicians to detect high-risk populations. Integrating HGI into routine clinical practice might strengthen the prognosis-based decision making improve HF patient outcomes.

求助全文
约1分钟内获得全文 求助全文
来源期刊
Diabetology & Metabolic Syndrome
Diabetology & Metabolic Syndrome ENDOCRINOLOGY & METABOLISM-
CiteScore
6.20
自引率
0.00%
发文量
170
审稿时长
7.5 months
期刊介绍: Diabetology & Metabolic Syndrome publishes articles on all aspects of the pathophysiology of diabetes and metabolic syndrome. By publishing original material exploring any area of laboratory, animal or clinical research into diabetes and metabolic syndrome, the journal offers a high-visibility forum for new insights and discussions into the issues of importance to the relevant community.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信